Search
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Kappadione
go.drugbank.com/drugs/DB09332ApprovedIt has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. … Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].
Carmofur
go.drugbank.com/drugs/DB09010ApprovedWithdrawnCarmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
Phenylmercuric acetate
go.drugbank.com/drugs/DB17044ExperimentalPhenylmercuric acetate is an organomercurial compound used as a fungicide and slimicide.[A253082]
Categories: Compounds used in a research, industrial, or household settingAffitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAffitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease. … AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.
GTS-21
go.drugbank.com/drugs/DB05708Investigationalrelated and memory related tasks (Kitagawa, et al. … GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated.
ATN-161
go.drugbank.com/drugs/DB05491InvestigationalIt inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigational[A255111] Nadofaragene firadenovec is formulated with an excipient (Syn-3) that facilitates gene transfer across the urothelium and promotes the transduction of IFNα2b. … [L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS)